Skip to main content
SpringerLink
Log in

TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome

  • Chapter
  • First Online:
p53 in the Clinics

Abstract

Li–Fraumeni syndrome (LFS) is a rare autosomal dominantly inherited cancer predisposition disorder commonly associated with germline TP53 mutations. The syndrome classically presents with a wide spectrum of childhood and adult-onset cancers. Penetrance of the cancer phenotype is high with a lifetime risk of >75 % to develop cancer in TP53 mutation carriers. The spectrum of germline TP53 mutations is similar to that observed for somatic TP53 mutations in sporadic cancers. Studies to explore the genetic and epigenetic events that modify the cancer phenotype in LFS families have identified several polymorphisms in TP53, as well as in other genes that regulate TP53 function. In addition, other global genetic/genomic features including excessive DNA copy number variation and accelerated telomere attrition have been implicated in modifying phenotype conferred by the primary TP53 defect. Genetic testing for TP53 mutations in LFS family members is now commonly used to identify at-risk individuals. Based on this information, and in the context of multidisciplinary genetic counseling teams, novel approaches to clinical surveillance for early cancer detection are being implemented. In the 20 years from discovery of the link between germline TP53 mutations and etiology of LFS, translation of basic discoveries in TP53 biology to clinical application in terms of tumor prognosis, therapy, and early detection has made significant impact on the lives of patients in these families.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2(7):811–814

    PubMed  CAS  Google Scholar 

  • Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245(1–2):96–102

    PubMed  CAS  Google Scholar 

  • Assumpcao JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA (2008) Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8:357

    PubMed  Google Scholar 

  • Atwal GS, Bond GL, Metsuyanim S, Papa M, Friedman E, Distelman-Menachem T, Ben Asher E, Lancet D, Ross DA, Sninsky J, White TJ, Levine AJ, Yarden R (2007) Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci USA 104(11):4524–4529

    PubMed  CAS  Google Scholar 

  • Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R (2005) Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res 65(2):427–431

    PubMed  CAS  Google Scholar 

  • Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286(5449):2528–2531

    PubMed  CAS  Google Scholar 

  • Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA (1998) Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77(7):1130–1136

    PubMed  CAS  Google Scholar 

  • Birch JM (1994) Li-Fraumeni syndrome. Eur J Cancer 30A(13):1935–1941

    PubMed  CAS  Google Scholar 

  • Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibanez-Koref MF (1994) Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70(6):1176–1181

    PubMed  CAS  Google Scholar 

  • Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17(9):1061–1068

    PubMed  CAS  Google Scholar 

  • Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20(34):4621–4628

    PubMed  CAS  Google Scholar 

  • Boldrini L, Gisfredi S, Ursino S, Lucchi M, Greco G, Mussi A, Donati V, Fontanini G (2008) Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 26(2):168–172

    PubMed  CAS  Google Scholar 

  • Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591–602

    PubMed  CAS  Google Scholar 

  • Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66(10):5104–5110

    PubMed  CAS  Google Scholar 

  • Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1–00): a randomised phase 3 trial. Lancet Oncol 12(6):527–539

    PubMed  CAS  Google Scholar 

  • Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52(11):3234–3236

    PubMed  CAS  Google Scholar 

  • Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S et al (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14(1):71–75

    PubMed  CAS  Google Scholar 

  • Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4(1):203–210

    PubMed  CAS  Google Scholar 

  • Bougeard G, Brugieres L, Chompret A, Gesta P, Charbonnier F, Valent A, Martin C, Raux G, Feunteun J, Bressac-de Paillerets B, Frebourg T (2003) Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 22(6):840–846

    PubMed  CAS  Google Scholar 

  • Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8):535–538

    PubMed  CAS  Google Scholar 

  • Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713

    PubMed  CAS  Google Scholar 

  • Cavalier ME, Davis MM, Croop JM (2005) Germline p53 mutation presenting as synchronous tumors. J Pediatr Hematol Oncol 27(8):441–443

    PubMed  Google Scholar 

  • Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265(5170):346–355

    PubMed  CAS  Google Scholar 

  • Chompret A (2002) The Li-Fraumeni syndrome. Biochimie 84(1):75–82

    PubMed  CAS  Google Scholar 

  • Chompret A, Brugieres L, Bonaiti-Pellie C, Feunteun J (2004) Sex differences in cancer risk among germline p53 mutation carriers. Br J Cancer 91(3):603–604

    PubMed  CAS  Google Scholar 

  • Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA (2005) Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 175(9):5799–5808

    PubMed  CAS  Google Scholar 

  • Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M (2005) Tumour biology: senescence in premalignant tumours. Nature 436(7051):642

    PubMed  CAS  Google Scholar 

  • Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32

    PubMed  Google Scholar 

  • Custodio G, Taques GR, Figueiredo BC, Gugelmin ES, Oliveira Figueiredo MM, Watanabe F, Pontarolo R, Lalli E, Torres LF (2011) Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One 6(3):e18015

    PubMed  CAS  Google Scholar 

  • D’Orazio JA (2010) Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol 32(3):195–228

    PubMed  Google Scholar 

  • DiGiammarino EL, Filippov I, Weber JD, Bothner B, Kriwacki RW (2001) Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein. Biochemistry 40(8):2379–2386

    PubMed  CAS  Google Scholar 

  • Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D (1995) Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95(4):1606–1611

    PubMed  CAS  Google Scholar 

  • Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101–124

    PubMed  CAS  Google Scholar 

  • Farnebo M (2009) Wrap53, a novel regulator of p53. Cell Cycle 8(15):2343–2346

    PubMed  CAS  Google Scholar 

  • Farnebo M, Bykov VJ, Wiman KG (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396(1):85–89

    PubMed  CAS  Google Scholar 

  • Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC (1993) Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53(3):752–759

    PubMed  CAS  Google Scholar 

  • Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC (2006) Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43(1):91–96

    PubMed  CAS  Google Scholar 

  • Fiszer-Maliszewska L, Czernik J, Sawicz-Birkowska K, Perek D, Kozera M, Wojciechowska B, Kazanowska B, Hudziec P, Kilar E (2000) Screening for germline p53 mutations in pediatric and adult patients of high-risk groups in Poland. Arch Immunol Ther Exp (Warsz) 48(4):309–315

    CAS  Google Scholar 

  • Friedlander P, Haupt Y, Prives C, Oren M (1996) A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16(9):4961–4971

    PubMed  CAS  Google Scholar 

  • Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61(6):2505–2512

    PubMed  CAS  Google Scholar 

  • Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9(15):5582–5588

    PubMed  CAS  Google Scholar 

  • Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23(10):1954–1956

    PubMed  CAS  Google Scholar 

  • Goh HS, Yao J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55(22):5217–5221

    PubMed  CAS  Google Scholar 

  • Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256

    PubMed  CAS  Google Scholar 

  • Grochola LF, Vazquez A, Bond EE, Wurl P, Taubert H, Muller TH, Levine AJ, Bond GL (2009) Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clin Cancer Res 15(19): 6301–6308

    PubMed  CAS  Google Scholar 

  • Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6(12):4650–4656

    PubMed  CAS  Google Scholar 

  • Hartley AL, Birch JM, Blair V (1991) Malignant disease in the mothers of a population-based series of young adults with bone and soft tissue sarcomas. Br J Cancer 63(3):416–419

    PubMed  CAS  Google Scholar 

  • Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, Mathieu MC, Marsiglia H, Bourgier C (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104

    PubMed  Google Scholar 

  • Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ 1(12):571–580

    PubMed  CAS  Google Scholar 

  • Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90(8):606–611

    PubMed  CAS  Google Scholar 

  • Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100(1):143–148

    PubMed  CAS  Google Scholar 

  • Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65(20):9582–9587

    PubMed  CAS  Google Scholar 

  • Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72(4):975–983

    PubMed  CAS  Google Scholar 

  • Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321–1328

    PubMed  CAS  Google Scholar 

  • Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150(1):1–13

    PubMed  CAS  Google Scholar 

  • Kleinerman RA (2009) Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 39(Suppl 1):S27–S31

    PubMed  Google Scholar 

  • Kony SJ, de Vathaire F, Chompret A, Shamsaldim A, Grimaud E, Raquin MA, Oberlin O, Brugieres L, Feunteun J, Eschwege F, Chavaudra J, Lemerle J, Bonaiti-Pellie C (1997) Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 350(9071):91–95

    PubMed  CAS  Google Scholar 

  • Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R (1999) Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35(3):398–405

    PubMed  CAS  Google Scholar 

  • Lalloo F, Varley J, Moran A, Ellis D, O’Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143–1150

    PubMed  CAS  Google Scholar 

  • Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ (2010) Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 29(9):1329–1338

    PubMed  CAS  Google Scholar 

  • Lammens CR, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, Vriends AH, Ruijs MW, van Os TA, Spruijt L, Gomez Garcia EB, Kluijt I, Nagtegaal T, Verhoef S, Bleiker EM (2010) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008–3014

    PubMed  Google Scholar 

  • Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861–872

    PubMed  CAS  Google Scholar 

  • Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B (1993) Simple sequence repeat polymorphism within the p53 gene. Oncogene 8(6):1703–1705

    PubMed  CAS  Google Scholar 

  • Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778

    PubMed  CAS  Google Scholar 

  • Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747–752

    PubMed  CAS  Google Scholar 

  • Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362

    PubMed  CAS  Google Scholar 

  • Li YJ, Sanson M, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R (1995) Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 64(6):383–387

    PubMed  CAS  Google Scholar 

  • Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME (2005) The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280(25):24245–24251

    PubMed  CAS  Google Scholar 

  • Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M (2009) Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33(4):462–471

    PubMed  CAS  Google Scholar 

  • Malkin D (2001) The role of p53 in human cancer. J Neurooncol 51(3):231–243

    PubMed  CAS  Google Scholar 

  • Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238

    PubMed  CAS  Google Scholar 

  • Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J et al (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326(20): 1309–1315

    PubMed  CAS  Google Scholar 

  • Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299(11): 1315–1319

    PubMed  CAS  Google Scholar 

  • Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7(2):961–963

    PubMed  CAS  Google Scholar 

  • Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23(38):6445–6470

    PubMed  CAS  Google Scholar 

  • Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10(2):83–87

    PubMed  CAS  Google Scholar 

  • Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P et al (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342(6250):705–708

    PubMed  CAS  Google Scholar 

  • Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119(6):847–860

    PubMed  CAS  Google Scholar 

  • Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20):6643–6650

    PubMed  CAS  Google Scholar 

  • Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008

    PubMed  Google Scholar 

  • Ory K, Legros Y, Auguin C, Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13(15):3496–3504

    PubMed  CAS  Google Scholar 

  • Palmero EI, Schuler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P (2008) Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261(1):21–25

    PubMed  CAS  Google Scholar 

  • Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P (2010) Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 22(1):64–69

    PubMed  CAS  Google Scholar 

  • Pearson AD, Craft AW, Ratcliffe JM, Birch JM, Morris-Jones P, Roberts DF (1982) Two families with the Li-Fraumeni cancer family syndrome. J Med Genet 19(5):362–365

    PubMed  CAS  Google Scholar 

  • Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165

    PubMed  CAS  Google Scholar 

  • Pierce LJ, Haffty BG (2011) Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol 21(1):43–50

    PubMed  Google Scholar 

  • Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91(6):1998–2002

    PubMed  CAS  Google Scholar 

  • Pleasants LM, Hansen MF (1994) Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet 93(5):607–608

    PubMed  CAS  Google Scholar 

  • Potzsch C, Voigtlander T, Lubbert M (2002) p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies. J Cancer Res Clin Oncol 128(8):456–460

    PubMed  Google Scholar 

  • Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98(16):9330–9335

    PubMed  CAS  Google Scholar 

  • Rich DC, Corpron CA, Smith MB, Black CT, Lally KP, Andrassy RJ (1997) Second malignant neoplasms in children after treatment of soft tissue sarcoma. J Pediatr Surg 32(2):369–372

    PubMed  CAS  Google Scholar 

  • Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15(4):827–838

    PubMed  CAS  Google Scholar 

  • Royds JA, Iacopetta B (2006) p53 and disease: when the guardian angel fails. Cell Death Differ 13(6):1017–1026

    PubMed  CAS  Google Scholar 

  • Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van ’t Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421–428

    PubMed  CAS  Google Scholar 

  • Sandrini R, Ribeiro RC, DeLacerda L (1997) Childhood adrenocortical tumors. J Clin Endocrinol Metab 82(7):2027–2031

    PubMed  CAS  Google Scholar 

  • Shlien A (2010) Differential phenotypic impact of large genic versus small intragenic deletions across TP53. Amer J Human Genet 87(5):631–642

    Google Scholar 

  • Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, Nanda S, Druker H, Scherer SW, Malkin D (2008) Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA 105(32): 11264–11269

    PubMed  CAS  Google Scholar 

  • Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52(10):2984–2986

    PubMed  CAS  Google Scholar 

  • Sodha N, Williams R, Mangion J, Bullock SL, Yuille MR, Eeles RA (2000) Screening hCHK2 for mutations. Science 289(5478):359

    PubMed  CAS  Google Scholar 

  • Sodha N, Houlston RS, Bullock S, Yuille MA, Chu C, Turner G, Eeles RA (2002) Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 20(6):460–462

    PubMed  CAS  Google Scholar 

  • Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1(3):233–240

    PubMed  CAS  Google Scholar 

  • Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331(3):834–842

    PubMed  CAS  Google Scholar 

  • Soussi T, Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12(4):303–312

    PubMed  CAS  Google Scholar 

  • Staples OD, Steele RJ, Lain S (2008) p53 as a therapeutic target. Surgeon 6(4):240–243

    PubMed  CAS  Google Scholar 

  • Tabori U, Malkin D (2008) Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 68(7):2053–2057

    PubMed  CAS  Google Scholar 

  • Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 67(4):1415–1418

    PubMed  CAS  Google Scholar 

  • Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28(12):1995–2001

    PubMed  CAS  Google Scholar 

  • Talwalkar SS, Yin CC, Naeem RC, Hicks MJ, Strong LC, Abruzzo LV (2010) Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med 134(7):1010–1015

    PubMed  Google Scholar 

  • Taylor MD, Mainprize TG, Rutka JT (2000) Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 47(4):888–901

    PubMed  CAS  Google Scholar 

  • Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaiti-Pellie C, Stoppa-Lyonnet D, Frebourg T (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108–e109, author reply e110

    PubMed  Google Scholar 

  • Trahair T, Andrews L, Cohn RJ (2007) Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer 48(3):345–348

    PubMed  CAS  Google Scholar 

  • Trkova M, Hladikova M, Kasal P, Goetz P, Sedlacek Z (2002) Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome? J Hum Genet 47(8):381–386

    PubMed  Google Scholar 

  • Trkova M, Prochazkova K, Krutilkova V, Sumerauer D, Sedlacek Z (2007) Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 110(3):694–702

    PubMed  CAS  Google Scholar 

  • Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61(15):5718–5722

    PubMed  CAS  Google Scholar 

  • Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21(3):313–320

    PubMed  CAS  Google Scholar 

  • Varley JM, Evans DG, Birch JM (1997) Li-Fraumeni syndrome – a molecular and clinical review. Br J Cancer 76(1):1–14

    PubMed  CAS  Google Scholar 

  • Varley JM, McGown G, Thorncroft M, Kelsey AM, Birch JM (2001) Significance of intron 6 sequence variations in the TP53 gene in Li-Fraumeni syndrome. Cancer Genet Cytogenet 129(1):85–87

    PubMed  CAS  Google Scholar 

  • Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844–848

    PubMed  CAS  Google Scholar 

  • Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7(12):979–987

    PubMed  CAS  Google Scholar 

  • Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559–567

    PubMed  CAS  Google Scholar 

  • Vogel JM, Shannon KM (2009) Genetic counseling and testing for Li-Fraumeni syndrome: the medical and psychosocial implications. Commun Oncol 6:507–514

    Google Scholar 

  • Warner E (2011) Clinical practice. Breast-cancer screening. N Engl J Med 365(11):1025–1032

    PubMed  CAS  Google Scholar 

  • Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Murphy JM, Narod SA (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19(15):3524–3531

    PubMed  CAS  Google Scholar 

  • Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9(2):95–107

    PubMed  CAS  Google Scholar 

  • Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130(1):73–79

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genetics and Genome Biology Program, Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, Canada, M5G 1X8

    Doua Bakry M.D. & David Malkin M.D.

Authors
  1. Doua Bakry M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Malkin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Malkin M.D. .

Editor information

Editors and Affiliations

  1. International Prevention Research Instit, 95 cours Lafayette, Lyon, 69006, France

    Pierre Hainaut

  2. International Agency for Cancer Research, 150 Cours Albert-Thomas, Lyon, 69372, France

    Magali Olivier

  3. Cancer Center Karolinska (CCK), Dept. Oncology and Pathology, Karolinska Institute, Karolinska Institutet, Stockholm, 171 76, Sweden

    Klas G. Wiman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bakry, D., Malkin, D. (2013). TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome. In: Hainaut, P., Olivier, M., Wiman, K. (eds) p53 in the Clinics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3676-8_10

Download citation

Publish with us

Policies and ethics

Search

Navigation